The FDA approves Zepbound, originally used for type 2 diabetes and weight loss, for treating obstructive sleep apnea (OSA) in obese adults. Developed by Eli Lilly, this drug offers an alternative to traditional breathing devices, addressing both obesity and sleep apnea. Long-term monitoring is advised.
